Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections

Exclusion Criteria

• •The participant has a BMI \>= 40.0 kg/ m\^2 or a BMI \>=35.0 kg/ m\^2 with obesity related health conditions such as high blood pressure or uncontrolled diabetes (non-fasting glucose value \>300 milligram/deciliter \[mg/dL\])
• •The participant is immunocompromised or has altered immune defenses that may predispose the participant to a higher risk of treatment failure and/or complications
• •The participant has symptoms known or suspected to be caused by another disease process, such as asymptomatic bacteriuria, overactive bladder, chronic incontinence, or chronic interstitial cystitis
• •The participant has an anatomical or physiological anomaly that predisposes the participant to UTIs or may be a source of persistent bacterial colonization, including calculi, obstruction of the urinary tract, primary renal disease, or neurogenic bladder, or the participant has a history of anatomical or functional abnormalities of the urinary tract
• •The participant has an indwelling catheter, nephrostomy, ureteral stent, or other foreign material in the urinary tract
• •The participant who, in the opinion of the investigator, has an otherwise complicated UTI, an active upper UTI (e.g., pyelonephritis, urosepsis), signs and symptoms onset \>=96 hours before the screening assessment, or a temperature \>=101-degree Fahrenheit (°F) (\>=38 degree Celsius \[°C\]), flank pain, chills, or any other manifestations suggestive of upper UTI
• •The participant has anuria, oliguria, or significant impairment of renal function
• •The participant presents at enrollment with a suspected sexually transmitted infection
• •A positive confirmation of Coronavirus Disease 2019 (COVID-19) infection, or high clinical index of suspicion for COVID-19
• •The participant has received treatment with other systemic antimicrobials or systemic antifungals within 1 week or 10 weeks for dalbavancin or oritavancin before study entry.
• •Regular alcohol consumption within 6 months prior to the study with an average weekly intake of \>14 units for females and one unit is equivalent to approximately 8 g of alcohol: a half-pint (250 mL) of beer, one glass (125 mL) of wine or one (35 mL) measure of spirits
• •Unable to take nitrofurantoin. E.g. hypersensitivity to the active substance